deltatrials

Hereditary angioedema (hae) Trials in Ottawa, Canada

Conditions / Hereditary angioedema (hae) / Ottawa, Canada

Hereditary angioedema (hae) is a medical condition with active clinical research programs worldwide.

10 total trials for this combination

Trials

NCT ID Title Status Phase
NCT02741596 Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE COMPLETED PHASE3
NCT06842823 A Study of Navenibart in Participants With Hereditary Angioedema RECRUITING PHASE3
NCT06669754 Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE ACTIVE_NOT_RECRUITING PHASE3
NCT05819775 CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema COMPLETED PHASE3
NCT02586805 Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE COMPLETED PHASE3
NCT00456508 Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) COMPLETED PHASE3
NCT07428499 Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) RECRUITING
NCT00457015 Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) COMPLETED PHASE3
NCT04583007 Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults NO_LONGER_AVAILABLE
NCT02584959 Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema COMPLETED PHASE3

Related Pages